Effective connectivity of emotion and cognition under psilocybin

Devon Stoliker[1,2*], Leonardo Novelli[1,2], Franz X. Vollenweider[3], Gary F. Egan[1,2], Katrin H. Preller[3 +],
Adeel Razi[1,2,4,5 +]

[1]Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC
[2] Monash Biomedical Imaging, Monash University, Clayton, VIC
[3] Department of Psychiatry, Psychotherapy & Psychosomatics, Psychiatric University Hospital Zurich,
Zurich, Switzerland
[4] Wellcome Centre for Human Neuroimaging, UCL, London, United Kingdom
[5]CIFAR Azrieli Global Scholars Program, CIFAR, Toronto, Canada

+ Joint Senior Authors

Abstract

Classic psychedelics alter sense of self and patterns of self-related thought. These changes are

hypothesised to underlie their therapeutic efficacy across internalising pathologies such as addiction and

depression. Using resting-state functional MRI images from a randomised, double blinded, placebo-

controlled clinical trial of 24 healthy adults under 0.215mg/kg psilocybin, we investigated how psilocybin

modulates the effective connectivity between resting state networks and the amygdala that are involved in

the appraisal and regulation of emotion and association with clinical symptoms. The networks included

the default mode network (DMN), salience network (SN) and central executive network (CEN).

Psilocybin decreased top-down effective connectivity from the resting state networks to the amygdala and

decreased effective connectivity within the DMN and SN, while the within CEN effective connectivity

increased. Effective connectivity changes were also associated with altered emotion and meaning under

psilocybin. Our findings identify changes to cognitive-emotional connectivity associated with the

subjective effects of psilocybin and the attenuation of the amygdala signal as a potential biomarker of

psilocybin's therapeutic efficacy.

Keywords – fMRI, psychedelics, resting state connectivity, dynamic causal modelling, psilocybin,

emotion, cognition, amygdala

Introduction

Psilocybin, the main active compound of so-called magic mushrooms, is a serotonergic psychedelic that

has been used throughout history in religious and medical rituals to alter consciousness (Carod-Artal,

2015; Nichols, 2016). It belongs to a larger group of substances such as ayahuasca (DMT) and mescaline

that share molecular binding kinetics to serotonergic 5-HT receptors distributed throughout the brain

(Nichols, 2012). Agonism of the 5-HT2A receptor is primarily responsible for psychedelic subjective

effects that can cause powerful changes to subjective experience (Vollenweider et al 1998; (Kometer et

al., 2012) Kometer et al. 2013; Preller et al. 2017; Kraehenmann et al. 2017). Psychedelics can also

produce feelings of subjective wellbeing (Hirschfeld & Schmidt, 2020) and profound changes in self-

awareness and perception, including visual hallucinations and synaesthesia, and a sense of transcendence

of time and space (Studerus, Gamma, & Vollenweider, 2010; Swanson, 2018; Wittmann et al., 2007;

(Stoliker, Egan, Friston, & Razi, 2022). Altered (self-)perception and self-awareness are unique effects of

serotonergic psychedelics and may involve an experience of ego dissolution, defined as a loss of self-

boundaries and sense of unity between the self and the environment (Stoliker, Egan, Friston, & Razi,

2021; Stoliker, Egan, Friston, et al., 2022)Lebedev et al., 2015). Although complete ego dissolution is

rare at the medium dose potency used in clinical trials, several studies have found that overall blissful ego

dissolution (as measured by the total mystical score or oceanic self-boundlessness) is associated with

better long-term outcomes in healthy subjects (Griffiths et al., 2011) and reduced symptoms of depression

(Griffiths et al., 2016; Roseman, Nutt, & Carhart-Harris, 2018; Ross et al., 2016) and addiction

(Bogenschutz et al., 2015; Garcia-Romeu, Griffiths, & Johnson, 2014).

Depression has been linked to a fundamental sense of disconnectedness (Northoff, 2007), which may be

ameliorated by psychedelics. Studies have found reduced depression scores and improved wellness

associated with enhanced the subjective sense of connectedness following an acute psychedelic

experience (R. L. Carhart-Harris et al., 2018; Watts, Day, Krzanowski, Nutt, & Carhart-Harris, 2017;

Watts et al., 2022). Research findings indicate a strong correlation between ratings of psychological

insight one day after a session with psilocybin and decreases in depression four weeks later (Alan K.

Davis et al., 2021). Reduced depression may also be mediated by increased cognitive and psychological

flexibility after psychedelics (A. K. Davis, Barrett, & Griffiths, 2020; Doss et al., 2021). These findings

suggest that the long-term benefits of psychedelics for mental health may result from modulation of the

regulation of emotions and cognitive processing (Duerler, Vollenweider, & Preller, 2022; Franz X.

Vollenweider & Preller, 2020). Moreover, the acute psychedelic experience appears to be crucial to these

changes.

The amygdala is a bilateral subcortical region composed of many subnuclei that integrate cortical and

thalamic sensory inputs (Babaev, Piletti Chatain, & Krueger-Burg, 2018). Its primary function is to

respond to the emotional significance of stimuli and regulate arousal (Alexander et al., 2021; Bonnet et

al., 2015). For example, presentations of positive or negative emotional stimuli, such as physical threats,

elicit activation of the amygdala (Alexander et al., 2021; Garavan, Pendergrass, Ross, Stein, & Risinger,

2001; Hobin, Goosens, & Maren, 2003; Weymar & Schwabe, 2016). The amygdala also responds to

cognitive-emotional significance. For example, when personal beliefs are threatened (Kaplan, Gimbel, &

Harris, 2016). This demonstrates self-beliefs can condition and regulate amygdala emotional responses.

Similarly, complex emotions such as shame are associated with the amygdala and can be diminished by

its damage (Piretti et al., 2020). Emotional empathy is also associated with amygdala function (Geng et

al., 2018; Hillis, 2014; Marsh et al., 2013), and has been reported to be modified by psilocybin (Pokorny,

Preller, Kometer, Dziobek, & Vollenweider, 2017; Preller et al., 2015).

Further associations between emotional and behaviour regulation and the amygdala are demonstrated by

damage to the amygdala which affects decision-making (Gupta, Koscik, Bechara, & Tranel, 2011) and

memory (Adolphs, Tranel, & Denburg, 2000). Amygdala hyperactivation is also a marker of stress and

anxiety, which are implicated across internalising disorders for which psychedelics demonstrate efficacy

(Nutt & Carhart-Harris, 2020); Koob & Volkow, 2010; Luo, Xue, Shen, & Lu, 2013; Menon, 2011).

Emotional regulation depends on top-down and bottom-up modulation of the amygdala (McRae, Misra,

Prasad, Pereira, & Gross, 2012; Ochsner et al., 2009) and appears to be altered by psychedelics. For

example, healthy adults administered psilocybin show reduced effective connectivity from the amygdala

to the primary visual cortex coincident with reduced threat processing (Kraehenmann et al., 2015)

(Kraehenmann et al., 2016). The semisynthetic psychedelic drug lysergic diethylamide acid (LSD) has

also been shown to dampen the amygdala response to fearful stimuli (Mueller et al., 2017; Barrett, Doss,

Sepeda, Pekar, & Griffiths, 2020). Furthermore, decreased amygdala activity has been correlated with

positive mood under psilocybin lasting up to one month (Kraehenmann et al., 2015; Barrett et al., 2020).

However, subjects with treatment resistant depression imaged one day post-treatment show increased

amygdala responses to stimuli with psilocybin as well as improvements in depressive symptoms

(Roseman, Demetriou, Wall, Nutt, & Carhart-Harris, 2018; Barrett et al., 2020). Together, these results

suggest a change in amygdala connectivity under the acute influence of psychedelics may be a biological

mechanism underwriting the beneficial, mood-enhancing effects of psilocybin.

The amygdala is integrated with cognition through top-down projections from midline cortical regions

(Etkin et al., 2011; Kraehenmann et al., 2016; Robinson et al., 2013). These projections are thought to

underlie the perception and intensity of positive and negative emotions (Bonnet et al., 2015) and abnormal

connectivity of this circuitry underlies psychopathological conditions such as anxiety disorders (Menon,

2011). Amygdala connectivity changes that involve frontal cortical regions have been found in several

studies suggesting psilocybin modulates the top-down control of limbic regions involved in emotional

processing (Bernasconi et al., 2014; Mertens et al., 2020; Mueller et al., 2017; Barrett et al., 2020). Changes

to the amygdala and cortical regions are sustained well beyond the half-life of psilocybin and may last up

to one month post administration (Barrett, Doss, Sepeda, Pekar, & Griffiths, 2020), demonstrating the

lasting neural changes in association with increased positive affect.

Emotion is a flexible, dynamic and functionally integrated with cognitive regions of the brain (Lindquist,

Satpute, Wager, Weber, & Barrett, 2016). The function of cortical regions linked to amygdala are related

to the sense of self, self-referential cognition, cognitive appraisal, and emotional regulation. For example,

limbic-cortical dysregulation has been reported to impact mood regulation (Zeng et al., 2012). The

changes to cortical regions under the acute effects of psychedelics may modulate subcortical regions that

disrupt affective responses that may potentially support therapeutic responses.

Here we investigate to what extent psilocybin modulates the relationship of cognitive-emotional networks

interactions that may be relevant for therapeutic outcomes. We investigated amygdala connectivity to

regions that form frontal and anterior nodes of distinct large-scale resting-state networks (RSNs). RSNs

are determined by temporally correlated activation across spatially distributed brain regions and serve

essential functions in cognition (Fox et al., 2005; Raichle, 2015). The RSN regions of particular relevance

to this study are abundant in 5-HT2A receptors (Saulin, Savli, & Lanzenberger, 2012; R. L. Carhart-

Harris & Friston, 2019) and include the default mode network (DMN), central executive network (CEN)

and the salience network (SN).

The DMN integrates internal and external information to perform self-referential mental activity involved

in forming self-beliefs (Amey, Leitner, Liu, & Forbes, 2022; Tompson, Chua, & Kitayama, 2016) and is

composed of the medial prefrontal cortex (mPFC) and posterior cingulate cortex (PCC) central hub

regions. Increased DMN connectivity with the amygdala is observed in depressed subjects (Sheline

Yvette et al., 2009) and has been associated with symptoms such as rumination (Cooney, Joormann,

Eugène, Dennis, & Gotlib, 2010). In contrast, decreased coupling of the central hub regions of the DMN

was reported in association with the reduced mind wandering of advanced meditation practitioners

(Judson A. Brewer et al., 2011). Similar decoupling was found acutely (Carhart -Harris et al 2012) and

two days after psilocybin (R. L.; Smigielski, Scheidegger, Kometer, & Vollenweider, 2019). We

hypothesise reduced interactions between the amygdala and DMN and reduced within-DMN connectivity

may underpin an altered sense of self and self-related emotion under psychedelic subjective effects and

these subjective effects can be measured using the blissful state (emotion) and changed meaning of

percepts subscales of the 5D-ASC (Studerus, Gamma, & Vollenweider, 2010). Connectivity changes,

particularly those associated with subjective changes, may serve as a biomarker of connectivity that may

have therapeutic properties.

The central executive network (CEN) is a RSN involved in thinking, planning, and controlling attention

(Andrews-Hanna et al., 2014; Menon, 2011). Abnormal CEN function is associated with mental health in

various cognitive disorders. For example, reduced CEN activity has been associated with chronic

schizophrenia and depression (Leptourgos et al., 2020; Menon, 2011) and increased CEN-amygdala

connectivity was observed in association with catastrophising of chronic pain (Jiang et al., 2016). The

central hub regions of the CEN are the dorsolateral prefrontal cortex (dorsolateral PFC) and the lateral

posterior parietal cortex (lateral PPC). The dorsolateral PFC serves a primary role in regulating emotion

(Underwood et al., 2021) and was associated with worry in healthy adults and individuals with

generalised anxiety (Paulesu et al., 2010; Servaas et al., 2014; Jamieson, Harrison, Razi, & Davey, 2022).

Under psychedelics, a number of brain mapping studies suggest psychedelics increase the global

connectivity and flexibility of CEN connectivity that may be associated with subjective emotional

changes (Luppi et al., 2021; Tagliazucchi et al., 2016); Lord et al., 2019).

The salience network (SN) is a cognitive RSN involved in the detection of salient features in the

environment and disengages task-irrelevant activity associated with the DMN, for example during

daydreaming. The SN's cardinal regions are the dorsal anterior cingulate cortex (dorsal ACC) and anterior

insula (AI). Expanded network compositions of the SN also include the amygdala which may be

important for the initial emotional appraisal of salient stimuli. Overactive salience attributed to

hyperactivity of the AI or amygdala stimuli is a feature of various forms of psychopathology (Menon,

2011) and the AI is important to integrate affective and cognitive signals that influence interoceptive

responses related to psychosomatic symptoms and anxiety and depression (Paulus, 2006; Terasawa,

Shibata, Moriguchi, & Umeda, 2013 ;Wiebking et al., 2015). The dorsal ACC region of the SN is

activated in response to social pain (Rotge et al., 2015) that has been associated with changes in self-

processing (Smigielski et al. 2019; Smigielski et al., 2020) as well as reduced sense of social exclusion

under psilocybin (Preller et al., 2016; Preller et al., 2015). Observations under psilocybin have also shown

reduced SN integrity (Lebedev et al., 2015) and changes to effective connectivity from the SN to the

DMN under LSD (Stoliker, Novelli, et al., 2021). Psychedelics may alter salience functions that select the

pre-reflective channels of attention and modulate amygdala connectivity involved in emotional attention

and appraisal (Kapur, 2003; Stoliker, Egan, et al., 2021).

Results:

Network effective connectivity change with the amygdala under psilocybin

Participants underwent resting-state fMRI scans 70 minutes post oral administration of psilocybin.

Effective connectivity between the amygdala and the DMN, SN and CEN and brain-behaviour analysis

was performed at the group level using the framework of parametric empirical Bayes (PEB, see

supplementary material for details). The reported results for effective connectivity and brain-behaviour

analysis used a threshold of posterior probability > 0.99 for inference with very strong evidence. Those

connections and associations not reported did not exceed this threshold. For more statistical details, see

Supplementary Table 1.

i) *Change of DMN effective connectivity to the amygdala under psilocybin*

Group level effective connectivity strength between regions of the DMN and amygdala showed decreased

self-inhibition of the PCC (effect size = -0.21) and decreased effective connectivity from the PCC with

the left amygdala (effect size = -0.33 Hz) compared to placebo.

Fig 1. Default mode network effective connectivity change under psilocybin 70 minutes post-administration. Connections show changes in effective connectivity compared to placebo. Values display effect sizes (posterior expectations) of connections in Hz (except the inhibitory self-connections which are log-scaled). Values linked to subjective effects represent their associations with effective connectivity and represent normalized beta (β) coefficients. All results are for posterior probability > 0.99 (amounting to very strong evidence).

197
198   *ii)* *Change of CEN effective connectivity to the amygdala under psilocybin*

Several changes in effective connectivity were found, whose interplay is captured schematically in Fig. 2.

Specifically, group level effective connectivity strength between regions of the CEN and amygdala showed

increased self-inhibition of the right dorsolateral PFC (effect size = +0.17), left dorsolateral PFC (effect

size = +0.19) and decreased self-inhibition of the left lateral PPC (effect size = -0.2), compared to placebo.

Effective connectivity from the left lateral PPC to the left amygdala decreased (effect size = -0.22 Hz) and

increased from right lateral PPC to the right dorsolateral PFC (effect size = +0.2 Hz) and decreased to the

right amygdala (effect size = -0.39 Hz). Left dorsolateral PFC effective connectivity to the right amygdala

decreased (effect size = -0.16 Hz) and increased to the left lateral PPC (effect size = +0.23 Hz), while right

dorsolateral PFC increased to the left dorsolateral PFC (effect size = +0.15 Hz) and the right amygdala

increased to the left lateral PPC (effect size = +0.28 Hz), compared to placebo.

Fig 2. Central executive network effective connectivity change under psilocybin 70 minutes post-

administration. Values display effect sizes (posterior expectations) of connections in Hz (except the

inhibitory self-connections which are log-scaled). Values linked to subjective effects represent their

associations with effective connectivity and represent normalized β coefficients. All results are for posterior

probability > 0.99.

216
iii)   *Change of SN effective connectivity to the amygdala under psilocybin*

Group-level effective connectivity showed analysis showed increased self-inhibition of the right AI

(effect size = +0.23) and bilateral amygdala (effect size = +0.16 (right) and +0.31 (left)) and decreased

effective connectivity from the dorsal ACC to right amygdala (effect size = -0.19 Hz) and from left AI to

the right amygdala (effect size = -0.24 Hz) compared to placebo (Fig 3).

Fig 3. Salience network effective connectivity change under psilocybin 70 minutes post-administration.

Connections show changes in effective connectivity compared to placebo. Values display effect sizes

(posterior expectations) of connections in Hz (except the inhibitory self-connections which are log-scaled).

Values linked to subjective effects represent their associations with effective connectivity and represent

normalized β coefficients. All results are for posterior probability > 0.99.

Brain-behaviour associations

i)　　Behavioural associations to DMN-amygdala effective connectivity change under psilocybin

The brain-behaviour analysis showed negative association between self-connectivity of PCC and blissful

state (β coefficient = - 0.06), negative association between effective connectivity from PCC to left

amygdala and changed meaning of percept (β coefficient = - 0.04), and negative association between

effectivity from left amygdala to PCC and changed meaning of percept (β coefficient = - 0.06).   See Fig

1.

ii)   Behavioural associations to CEN-amygdala effective connectivity change under psilocybin

The brain-behaviour analysis showed positive association between effective connectivity from left lateral

PPC to right amygdala and blissful state (β coefficient = + 0.03), positive association between effective

connectivity from right DLPFC to left DLPFC and changed meaning of percept (β coefficient = + 0.03),

negative association between self-connectivity of left lateral PPC to changed meaning of percept (β

coefficient = - 0.04) ad blissful state (β coefficient = - 0.06), and positive association between effective

connectivity from left DLPFC to left lateral PPC and changed meaning of percept (β coefficient = + 0.07).

See Fig 2.

iii)   Behavioural associations to SN-amygdala effective connectivity change under psilocybin

The brain-behaviour analysis showed negative association between effective connectivity from left AI to

right amygdala and changed meaning of percept (β coefficient = - 0.06). See Fig 3.

Discussion:

To investigate the influence of psilocybin on the interaction between emotion and cognition, we measured

connectivity changes between the amygdala and selected RSNs. These networks serve functions in

selfhood and cognition and are composed of regions linked to the regulation and experience of emotion.

Our results demonstrate increased inhibitory effective connectivity from cortical regions to the amygdala

under psilocybin. For example, we showed this change in connectivity from the PCC, left dorsolateral

PFC, bilateral lateral PPC, dorsal ACC, and left AI. These results suggest cognitive resources do not

recruit the amygdala under psilocybin, and this modulation of top-down connectivity was related to

subjective effects of psilocybin.

Examination of the DMN-amygdala connectivity changes under psychedelics did not find effective

connectivity change involving the mPFC, which has been frequently cited in association with emotion,

such as emotional valence (Willinger et al., 2019; Underwood, Tolmeijer, Wibroe, Peters, & Mason,

2021). However, examination of the PCC, which orients information towards the self (Andrews-Hanna,

Smallwood, & Spreng, 2014; J. A. Brewer, Garrison, & Whitfield-Gabrieli, 2013 ; Qin & Northoff,

2011), and amygdala revealed connectivity changes and behavioural associations under psilocybin. PCC

and amygdala effective connectivity change was bidirectional and accompanied by reduced PCC self-

inhibition, which indicates increased synaptic gain or its sensitivity to inputs. The increased PCC synaptic

gain was associated with the subjective experience of blissful state, and PCC bidirectional inhibition with

the left amygdala was associated with changed meaning of percepts. Our findings suggest inhibition

between the amygdala and PCC may be an important connectivity change underlying altered meaning

(i.e., everyday things gained symbolic, strange, or emotional meaning), that, in turn, may contribute to the

change in self-awareness. Our findings also indicate PCC decreased inhibition facilitates blissful feelings.

These changes may reflect reduced top-down cognitive control associated with loss of self-referential

processing that is experienced as a dissolution of self-boundaries and align with the proposed role of the

PCC in self-referential processing (Brewer, Garrison, & Whitfield-Gabrieli, 2013; Qin & Northoff, 2011)

as well as previous evidence of PPC change associated to the dissolution of self-boundaries under

psychedelics (Muthukumaraswamy et al., 2013). For example, previous findings found PCC self-

inhibition under LSD, and the PCC's association with diminished self-representation in social interaction,

feelings of self and self-other processing under psychedelics (Preller et al., 2017; Preller et al., 2019;

Preller et al., 2018; Stoliker, Novelli, et al., 2022).

Left dorsolateral PFC and left lateral PPC inhibition to the amygdala was also observed and is situated

within the CEN. Connectivity in this network is believed to underlie the evaluative aspect of thought, with

the dorsolateral PFC playing a central role in emotional regulation. However, the observed increased top-

down inhibition of this connectivity to the amygdala was not associated with subjective effects assessed

with the 5D-ASC scale. Instead, the pattern of activity in this network is open to interpretation. One

characterisation of the observed activity may be its resemblance to hyper-frontality, which is associated

with worry and anxiety (Park, Wood, Bondi, Del Arco, & Moghaddam, 2016), and acute psychosis (F. X.

Vollenweider et al., 1997). There is also evidence that CEN connectivity is increased, and the amygdala

connectivity is decreased, during cognitive control strategies (Herwig et al., 2007; Herwig, Kaffenberger,

Jäncke, & Brühl, 2010). However, links between CEN activity and behaviour are suggested to be task and

context-dependent (Borders, 2020) and subjects in this study reported nominal anxiety, see Supplementary

Material. An alternative interpretation is that the observed connectivity pattern between regions of the CEN

constitutes an increase in evaluative thought processes and may be linked to re-appraisal. For example,

increased CEN and decreased amygdala activity of healthy adults was observed to increase during emotion-

introspection, while increased CEN and increased amygdala activity was associated with self-reflection

(Herwig et al., 2010). This literature may help explain the activation differences in the amygdala observed

between healthy adults under psychedelics and clinical populations in the days after psychedelics.

Moreover, increased CEN and decreased amygdala activity align our findings with connectivity underlying

emotion-introspection. Although the introspection of healthy adults in this imaging study was not assumed,

psilocybin experiences are commonly related to emotional introspection. Further evidence demonstrating

the therapeutic capacity of increased intrinsic CEN connectivity is presented in association with resilience

(Miller Gregory et al., 2018). Moreover, positive self-appraisal has been associated with increased CEN

and amygdala connectivity (Brühl, Rufer, Kaffenberger, Baur, & Herwig, 2014), which may relate to self-

reflection in the days after psilocybin administration. This evidence indicates the increased CEN

connectivity and CEN top-down inhibition to the amygdala as a connectivity change that relates to the

therapeutic potential of psilocybin for the revision of beliefs and it warrants further investigation.

Although we expect re-evaluation of thought under psychedelics to be influenced by the context (i.e., the mindset of participants and environmental setting), measured subjective effects associated with CEN connectivity changes are detectable in the imaging environment. For example, increased connectivity from the left dorsolateral PFC to the left lateral PPC and connectivity between the bilateral dorsolateral PFC was associated with changed meaning of percepts. Moreover, connectivity from the left dorsolateral PFC and right AMG to the left lateral PPC and decreased left lateral PPC self-inhibition were associated with both blissful state and the changed meaning of percepts. The lateral PPC inhibition to the amygdala may suggest its decoupling from the amygdala limits the sensory and interoceptive information to the amygdala, while the left amygdala synaptic gain increased. These results demonstrate nuanced modulation of the CEN-amygdala connectivity that align with previous reports of functional desegregation and expanded access to wider dynamics of brain states made available under psychedelics (Atasoy et al., 2017; Barnett, Muthukumaraswamy, Carhart-Harris, & Seth, 2019; R. L. Carhart-Harris & Nutt, 2017; A. K. Davis et al., 2020; Matias, Lottem, Dugué, & Mainen, 2017; Stoliker, Egan, & Razi, 2022; Tagliazucchi, Carhart-Harris, Leech, Nutt, & Chialvo, 2014; Watts & Luoma, 2020). These connectivity changes may be important to psilocybin's therapeutic potential that can be targeted to facilitate cognitive-emotional changes.

The ACC and AI serve essential functions in salience detection, and the integration of these regions with the amygdala may underwrite pathologically enhanced salience detection (Menon, 2011). These regions' inhibition of the right amygdala suggests their role in salience detection is diminished under psilocybin, which may be therapeutic for internalising disorders. Notably, previous literature found that psilocybin acutely reduced mainly the response in the right amygdala to negative stimuli, which may reflect "decentering" from one's emotion and thought that may facilitate reappraisal (Malinowski, 2013). However, inhibited salience detection also aligns with positive symptoms in schizophrenia (i.e., hallucinations and delusions) (Menon, 2011). At higher doses, psychedelics can induce a psychotic-like state in some individuals (F. X. Vollenweider, Vollenweider-Scherpenhuyzen, Babler, Vogel, & Hell,

1998), that may be related to the effect of serotonergic psychedelics on salience detection (Preller et al.,

2017). However, psychotic-like behavioural outcomes rarely occur in a controlled clinical setting (Johnson,

Richards, & Griffiths, 2008; Studerus, Gamma, Kometer, & Vollenweider, 2012; Studerus et al., 2010).

Previous research shows that increased functional connectivity between the AI and amygdala is associated

with relapse of addiction in preclinical studies (Venniro et al., 2017) and behavioural habituation in healthy

adults (Denny et al., 2014). Increased effect connectivity of this link has been associated with depression

in clinical populations (Kandilarova, Stoyanov, Kostianev, & Specht, 2018). The AI inhibition to the

amygdala was associated with changed meaning of percepts that suggests it may be associated with

therapeutic behavioural change. Previous task-based research shows reduced dorsal ACC activity in

association with blunted response to social exclusion under psilocybin (Preller et al., 2015). Although our

findings did not associate subjective effects with this connection, dorsal ACC-related inhibition aligns with

the inhibition of social pain (Preller et al., 2016; Preller et al., 2015) and previous findings of this circuit

implicate top-down inhibition in the resolution of emotional conflict (Etkin, Egner, Peraza, Kandel, &

Hirsch, 2006). DCM also estimated increased self-inhibition in the bilateral amygdala and rAI, suggesting

reduced synaptic gain of the regions. LSD produced similar results that demonstrated hypo-connectivity of

the right insula (Preller et al., 2018). However, the changes we observed were not associated with the

measured psychedelic subjective effects.

Taken together, our results suggest that psilocybin attenuates the recruitment of the amygdala. This

connectivity contributes to the altered meaning of percepts and subjective emotion. Diminished amygdala

activation has been related to emotional regulation (Herwig et al., 2019) and may alter the patterns of

connectivity that condition emotional, cognitive and self-reflective responses. Psilocybin induced change

to the RSNs that we observed generally aligns with previous literature that shows the increased flexibility

and transition of network states under psychedelics, as well as nimble and flexible brain networks are

instrumental to positive emotion and affect (Alexander et al., 2021). Therefore, the RSNs reduced

connectivity to the amygdala and altered within-RSN effective connectivity that we observed may be

important aspects of the subjective effects and emotional-cognitive connectivity changes that therapeutic

applications capitalise upon to encourage revision of beliefs.

Our endeavour to investigate interactions between emotion and cognition in a healthy population under

psilocybin has several limitations. For example, our analysis would benefit from MRI scans taken before

and after the administration of psilocybin. Exploring links between emotional and associative connectivity

also involves deciding network configuration and regions for analysis. Regions such as the ventral striatum,

precuneus, and parahippocampus and further subregions of the PFC and ACC may also be valuable for

examining the links between emotion and cognition (Underwood et al., 2021). Furthermore, each region

selected as part of the network may be determined differently depending on the method of identification of

the region. Further standardisation of this process is complex for anatomical reasons and remains under

debate. The processing pipeline, participant sample and dose of psilocybin can also strongly impact the

reliability of results. Participants were given lower doses than currently used in clinical studies of

depression and substance dependence disorders. Therefore, connectivity dynamics may be dissimilar at a

higher dose. Data sets at higher doses may provide improved inference and more nuanced characterisation

of the neural dynamics of interest. We also overlooked the influence of numerous neurotransmitter systems

involved in emotion that may interact with altered serotonin transmission. These interactions may provide

a novel line of inquiry to understand psychedelic therapeutic effects.

Other limitations in the methods and analysis include the use of global signal regression and the limited

temporal resolution. Temporal resolution is likely to be significant in the study of emotion. For example,

the time course of emotion may present distinct contributions of brain regions involved in valence and

arousal (Alexander et al., 2021). Modalities with temporal specificity capable of resolving insight and

emotional change, such as EEG or MEG, which can also be analysed using DCM, are needed in future

investigations. Furthermore, studies using task-based fMRI paradigms can induce activations in specific

emotion and cognition related brain regions (Brühl et al., 2014; Herwig et al., 2007; Herwig et al., 2010).

The generalisability of our results to clinical populations is limited by the use of a small healthy adult

sample and the congruence between our results and previous findings. Previous research indicates

psychedelics may globally increase bottom-up connectivity (R. Carhart-Harris, Kaelen, & Nutt, 2014; R.

L. Carhart-Harris & Friston, 2019; Swanson, 2018). For example, evidence of thalamic connectivity to the

cortex supports this view (Müller, Dolder, Schmidt, Liechti, & Borgwardt, 2018; Preller et al., 2019).

However, decoupling between limbic regions and the cortex has also been identified (Robin L. Carhart-

Harris et al., 2016; Lebedev et al., 2015). Our findings that identified increased bottom-up connectivity

from the right amygdala to the left lateral PPC align with the latter studies. As psychedelic research

advances, we suggest examination of multiple limbic regions and their subnuclei connectivity to the cortex.

This may reveal more precise and nuanced dynamics between the subcortex and cortex underlie previously

theorised global patterns. For example, recent investigations have demonstrated spatial specificity of

entropic activity and thalamic connectivity associated with psychedelic subjective effects (Gaddis et al.,

2022). Along these lines, the amygdala is composed of many subnuclei. Its small size, anatomical variability

and position deep within the brain presents challenges for noise-to-signal ratio and spatial location in group

fMRI analysis, which future imaging and research methods may overcome. Finally, increased excitation

among the CEN effective connectivity contrasts with previous analyses, which found a general reduction

in associative functional connectivity (Preller et al., 2020). While the global reduction of associative

connectivity may help explain experiences of ego dissolution, psychedelic experiences also contain

phenomenological richness (Millière, Carhart-Harris, Roseman, Trautwein, & Berkovich-Ohana, 2018).

Future research of CEN regions may wish to address the reliability of this effective connectivity and

examine links between the CEN, subjective experience, and therapeutic outcomes. Such work may benefit

from finer grained emotional and cognitive rating scales.

In sum, we demonstrated altered within-RSN effective connectivity and reduced top-down RSN-amygdala

effective connectivity associated with emotional and cognitive behavioural changes under psilocybin. The

functional significance of these changes to perceptual processes and psychopathology may be reduced

cognitive control and increased flexibility of these networks and the attenuated modulation of the amygdala

under the acute effects of psilocybin. These changes may enable a mental workspace for therapeutic

emotional and cognitive change. We suggest RSN attenuation of the amygdala as a potential biomarker for

future clinical research investigating the neural correlates of psychedelic therapeutic efficacy. Future work

may also build upon our effective connectivity findings to understand how connectivity underlying emotion

and cognition interact with the therapeutic context to effect patterns of thought and behaviour. These lines

of enquiry can help discern the imperative of the psychedelic subjective experience to therapeutic outcomes

and bridge gaps in our understanding of the relationship between brain connectivity and behaviour.

Methods

Participants

The data analysed in this paper were collected as part of a previous study (registered at ClinicalTrials.gov

(NCT03736980)), which is reported in (Preller et al., 2020) and was approved by the Cantonal Ethics

Committee of Zurich. Twenty-four subjects (12 males and 11 females; mean age = 26.3 y; range = 20–40

y; 1 subject did not complete the study) were recruited through advertisements at universities in Zurich,

Switzerland. All participants were deemed healthy after screening for medical history, physical

examination, blood analysis, and electrocardiography. The Mini-International Neuropsychiatric Interview

(MINI-SCID) (Sheehan et al., 1998), the DSM-IV fourth edition self-rating questionnaire for Axis-II

personality disorders (SCID-II) (Fydrich, Renneberg, Schmitz, & Wittchen, 1997), and the Hopkins

Symptom Checklist (SCL-90-R) (Franke, 2002) were used to exclude subjects with present or previous

psychiatric disorders or a history of major psychiatric disorders in first-degree relatives. Participants were

asked to abstain from prescription and illicit drug use two weeks prior to first testing and throughout the

duration of the study, and abstain from alcohol use 24 hours prior to testing days. Urine tests and self-report

questionnaires were used to verify the absence of drug and alcohol use. Urine tests were also used to exclude

pregnancy. Further exclusion criteria included left-handedness, poor knowledge of the German language,

cardiovascular disease, history of head injury or neurological disorder, history of alcohol or illicit drug

dependence, MRI exclusion criteria, including claustrophobia, and previous significant adverse reactions

to a hallucinogenic drug. All participants provided written informed consent statements in accordance with

the declaration of Helsinki before participation in the study. Subjects received written and oral descriptions

of the study procedures, as well as details regarding the effects and possible risks of drug treatment.

Design

A double blind, randomised, placebo-controlled, cross-over study was performed. Testing days occurred

two weeks apart and participants were orally administered either psilocybin (0.2mg/kg orally) or placebo

(179 mg mannitol and colloidal silicon dioxide (Aerosil) 1 mg. Resting state scans (10 minutes each) were

taken 20, 40 and 70 minutes following administration. However, only scans at 70 minutes during the peak

effects were used in our analysis. Participants were asked to not engage in repetitive thoughts such as

counting and instructed to close their eyes during the resting state scan. Subjective experience was assessed

using the retrospective 5-Dimensions Altered States of Consciousness (5D-ASC) questionnaire.

Participants completed the 5D-ASC 360 min following psilocybin administration, see Supplementary.

MRI Data Acquisition and Preprocessing

MRI data were acquired on a Philips Achieva 3T whole-body scanner. A 32-channel receive head coil and

MultiTransmit parallel radio frequency transmission was used. Images were acquired using a whole-brain

gradient-echo planar imaging (EPI) sequence (repetition time, 2,430 ms; echo time, 27 ms; slice thickness,

3 mm; 45 axial slices; no slice gap; field of view, 240×240 mm^2; in-plane resolution, 3×3 mm^2; sensitivity-

encoding reduction factor, 2.0). 265 volumes were acquired per resting state scan resulting in a scan

duration of 10 mins. Additionally, two high-resolution anatomical images (voxel size, $0.7 \times 0.7 \times 0.7$ mm^3)

were acquired using T1-weighted and T2-weighted sequences using 3D magnetization prepared rapid-

acquisition gradient echo sequence (MP-RAGE) and a turbo spin-echo sequence, respectively. See

Supplementary for more details. The acquired images were analysed using SPM12

(https://www.fil.ion.ucl.ac.uk).

The pre-processing steps of the images consisted of slice-timing correction, realignment, spatial

normalization to the standard EPI template of the Montreal Neurological Institute (MNI), and spatial

smoothing using a Gaussian kernel of 6-mm full-width at half maximum. Head motion was investigated

for any excessive movement. Three subjects were excluded due to head motion and one subject did not

complete the scan at 70 minutes.

Independent RSN-AMG DCM models

To reduce model complexity and focus the interpretation of the results on the connections of interest our

analysis investigated independent models of amygdala effective connectivity with the DMN, CEN and SN.

Extraction of region coordinates across subjects

Neurosynth, a large-scale automated synthesis of functional neuroimaging data, was used to identify

coordinates composing regions of interest (Yarkoni, Poldrack, Nichols, Van Essen, & Wager, 2011). More

details can be found in Supplementary Material.

Networks were composed of cardinal regions constituting core parts of the DMN (Andrews-Hanna,

Reidler, Sepulcre, Poulin, & Buckner, 2010; Dixon et al., 2017), SN and CEN. The DMN and SN

followed the selection of regions in a related investigation by Zhou and colleagues (Zhou et al., 2018) and

all networks were included for their role in consciousness and link to emotion (Alexander et al., 2021;

Borders, 2020; Underwood, Tolmeijer, Wibroe, Peters, & Mason, 2021). Associations between peak

coordinates and cardinal nodes of network regions of interest (ROI) were determined by expert visual

inspection. The MNI coordinates of the selected ROIs are listed in Table 1.

A generalized linear model (GLM) was used to regress 6 head motion parameters (3 translation and 3

rotational), white matter and cerebrospinal fluid signals from preprocessed data. One subject was excluded

as no activation was found in one or more regions of interest. We also used global signal regression in our

pre-processing pipeline in line with our previous work (Stoliker, Novelli, et al., 2021). The time series for

each ROI was computed as the first principal component of the voxel activity within a 6 mm radius sphere

centred on the ROI coordinates (as listed in Table 1).

Region	MNI coordinates			Network/System
	x	y	z	
PCC	0	-50	28	DMN
mPFC	0	54	20	DMN
dACC	2	28	22	SN
lAI	-34	19	0	SN
rAI	38	18	0	SN
ldPFC	-46	30	32	CEN
rdPFC	42	37	31	CEN
llPPC	-22	-62	62	CEN
rl PPC	19	-64	55	CEN
lAMG	-21	-5	-17	Limbic
rAMG	23	-3	-19	Limbic

Table 1 Coordinates of regions of interest. The DMN comprised of the posterior cingulate cortex (PCC) and

medial prefrontal cortex (mPFC); the SN comprised of the dorsal anterior cingulate cortex (dorsal ACC), left

and right anterior insula (lAI/rAI); and the CEN comprised the left and right dorsal lateral prefrontal cortex

(ldPFC/rd PFC) and the left and right lateral posterior parietal lobule (llPPC/rlPPC).

Specification and Inversion of DCM

Three independent fully-connected DCM models were specified for each network and the amygdala using

the eleven ROIs defined in Table 4, without any exogenous inputs. The DCM for each subject was then

inverted using spectral DCM (Karl J. Friston, Kahan, Biswal, & Razi, 2014; Razi, Kahan, Rees, & Friston,

2015) to infer the effective connectivity that best explains the observed cross-spectral density for each

subject. This procedure was repeated for each testing condition. The DCM fit to the data using cross spectral

density averaged 90.9% for placebo conditions and 89.8% for psilocybin conditions.

Second Level Analysis Using Parametric Empirical Bayes

The effective connectivity inferred by spectral DCM for each subject was taken to the second (group) level

to test hypotheses concerning between-group effects. A general linear model (GLM) was employed to

decompose individual differences in effective connectivity into hypothesised group-average connection

strengths together with unexplained noise. Hypotheses on the group-level parameters are tested within the

parametric empirical Bayes (PEB) framework (K. J. Friston et al., 2016), where both the expected values

and the covariance of the parameters were considered. That is, precise parameter estimates influence the

group-level result more strongly than uncertain estimates, which are down-weighted. Bayesian model

reduction (BMR) is used as an efficient form of Bayesian model selection (K. J. Friston et al., 2016). Please

see supplementary material for further technical details about PEB.

Author contributions:

Conceptualization: DS, AR, FXV

Methodology: DS, LN, AR

Investigation: DS, LN, AR

Visualization: DS, LN, AR

Supervision: AR

Writing—original draft: DS

Writing—review & editing: DS, LN, AR, GE, KP, FXV

References

Alexander, R., Aragón, O. R., Bookwala, J., Cherbuin, N., Gatt, J. M., Kahrilas, I. J., . . . Styliadis, C.
(2021). The neuroscience of positive emotions and affect: Implications for cultivating
happiness and wellbeing
. *Neuroscience & Biobehavioral Reviews, 121*, 220-249.
doi:https://doi.org/10.1016/j.neubiorev.2020.12.002
Andrews-Hanna, J. R., Reidler, J. S., Sepulcre, J., Poulin, R., & Buckner, R. L. (2010). Functional-
anatomic fractionation of the brain's default network. *Neuron, 65*(4), 550-562.
doi:10.1016/j.neuron.2010.02.005
Atasoy, S., Roseman, L., Kaelen, M., Kringelbach, M. L., Deco, G., & Carhart-Harris, R. L. (2017).
Connectome-harmonic decomposition of human brain activity reveals dynamical
repertoire re-organization under LSD. *Scientific Reports, 7*. doi:10.1038/s41598-017-
17546-0
Barnett, L., Muthukumaraswamy, S. D., Carhart-Harris, R. L., & Seth, A. K. (2019). Decreased
Directed Functional Connectivity in the Psychedelic State. *bioRxiv*, 703660.
doi:10.1101/703660
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). Emotions and brain
function are altered up to one month after a single high dose of psilocybin. *Sci Rep,
10*(1), 2214. doi:10.1038/s41598-020-59282-y
Bernasconi, F., Schmidt, A., Pokorny, T., Kometer, M., Seifritz, E., & Vollenweider, F. X. (2014).
Spatiotemporal brain dynamics of emotional face processing modulations induced by
the serotonin 1A/2A receptor agonist psilocybin. *Cereb Cortex, 24*(12), 3221-3231.
doi:10.1093/cercor/bht178
Bonnet, L., Comte, A., Tatu, L., Millot, J.-l., Moulin, T., & Medeiros de Bustos, E. (2015). The role
of the amygdala in the perception of positive emotions: an "intensity detector".
Frontiers in Behavioral Neuroscience, 9(178). doi:10.3389/fnbeh.2015.00178
Borders, A. (2020). Chapter 9 - Rumination, cognition, and the brain. In A. Borders (Ed.),
Rumination and Related Constructs (pp. 279-311): Academic Press.
Brewer, J. A., Garrison, K. A., & Whitfield-Gabrieli, S. (2013). What about the "Self" is Processed
in the Posterior Cingulate Cortex? *Front Hum Neurosci, 7*, 647.
doi:10.3389/fnhum.2013.00647
Brühl, A. B., Rufer, M., Kaffenberger, T., Baur, V., & Herwig, U. (2014). Neural circuits associated
with positive and negative self-appraisal. *Neuroscience, 265*, 48-59.
doi:10.1016/j.neuroscience.2014.01.053
Carhart-Harris, R., Kaelen, M., & Nutt, D. (2014). How do hallucinogens work on the brain?
Psychologist, 27(9), 662-665. Retrieved from <Go to ISI>://WOS:000341172000027
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., . . . Nutt,
D. J. (2018). Psilocybin with psychological support for treatment-resistant depression:
six-month follow-up. *Psychopharmacology, 235*(2), 399-408. doi:10.1007/s00213-017-
4771-x
Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the Anarchic Brain: Toward a Unified
Model of the Brain Action of Psychedelics. *Pharmacological Reviews, 71*(3), 316-344.
doi:10.1124/pr.118.017160

Carhart-Harris, R. L., & Nutt, D. J. (2017). Serotonin and brain function: a tale of two receptors.
Journal of Psychopharmacology, 31(9), 1091-1120. doi:10.1177/0269881117725915
Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations
between acute psychedelic effects and subjective decreases in depression and anxiety. *J
Contextual Behav Sci, 15*, 39-45. doi:10.1016/j.jcbs.2019.11.004
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., . . .
Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive
Disorder: A Randomized Clinical Trial. *JAMA Psychiatry, 78*(5), 481-489.
doi:10.1001/jamapsychiatry.2020.3285
Dixon, M. L., Andrews-Hanna, J. R., Spreng, R. N., Irving, Z. C., Mills, C., Girn, M., & Christoff, K.
(2017). Interactions between the default network and dorsal attention network vary
across default subsystems, time, and cognitive states. *NeuroImage, 147*, 632-649.
doi:10.1016/j.neuroimage.2016.12.073
Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., . . . Barrett,
F. S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with
major depressive disorder. *Translational psychiatry, 11*(1), 574. doi:10.1038/s41398-
021-01706-y
Duerler, P., Vollenweider, F. X., & Preller, K. H. (2022). A neurobiological perspective on social
influence: Serotonin and social adaptation. *J Neurochem, 162*(1), 60-79.
doi:10.1111/jnc.15607
Etkin, A., Egner, T., Peraza, D. M., Kandel, E. R., & Hirsch, J. (2006). Resolving Emotional Conflict:
A Role for the Rostral Anterior Cingulate Cortex in Modulating Activity in the Amygdala.
Neuron, 51(6), 871-882. doi:https://doi.org/10.1016/j.neuron.2006.07.029
Fox, M. D., Snyder, A. Z., Vincent, J. L., Corbetta, M., Van Essen, D. C., & Raichle, M. E. (2005).
The human brain is intrinsically organized into dynamic, anticorrelated functional
networks. *Proceedings of the National Academy of Sciences of the United States of
America, 102*(27), 9673. doi:10.1073/pnas.0504136102
Franke, G. (2002). *Die Symptom-Checkliste von Derogatis (SCL-90-R) - Deutsche Version -
Manual*.
Friston, K. J., Kahan, J., Biswal, B., & Razi, A. (2014). A DCM for resting state fMRI. *NeuroImage,
94*, 396-407. doi:https://doi.org/10.1016/j.neuroimage.2013.12.009
Friston, K. J., Litvak, V., Oswal, A., Razi, A., Stephan, K. E., van Wijk, B. C. M., . . . Zeidman, P.
(2016). Bayesian model reduction and empirical Bayes for group (DCM) studies.
NeuroImage, 128, 413-431. doi:10.1016/j.neuroimage.2015.11.015
Fydrich, T., Renneberg, B., Schmitz, B., & Wittchen, H. U. (1997). *SKID II. Strukturiertes Klinisches
Interview für DSM-IV, Achse II: Persönlichkeitsstörungen. Interviewheft. Eine
deutschspeachige, erw. Bearb. d. amerikanischen Originalversion d. SKID-II von: M.B.
First, R.L. Spitzer, M. Gibbon, J.B.W. Williams, L. Benjamin, (Version 3/96)*.
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., . .
. Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in
depression and anxiety in patients with life-threatening cancer: A randomized double-
blind trial. *Journal of Psychopharmacology, 30*(12), 1181-1197.
doi:10.1177/0269881116675513

Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011).
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related
effects. *Psychopharmacology, 218*(4), 649-665. doi:10.1007/s00213-011-2358-5

Herwig, U., Baumgartner, T., Kaffenberger, T., Brühl, A., Kottlow, M., Schreiter-Gasser, U., . . .
Rufer, M. (2007). Modulation of anticipatory emotion and perception processing by
cognitive control. *NeuroImage, 37*(2), 652-662. doi:10.1016/j.neuroimage.2007.05.023

Herwig, U., Kaffenberger, T., Jäncke, L., & Brühl, A. B. (2010). Self-related awareness and
emotion regulation. *NeuroImage, 50*(2), 734-741.
doi:10.1016/j.neuroimage.2009.12.089

Herwig, U., Lutz, J., Scherpiet, S., Scheerer, H., Kohlberg, J., Opialla, S., . . . Brühl, A. B. (2019).
Training emotion regulation through real-time fMRI neurofeedback of amygdala activity.
NeuroImage, 184, 687-696. doi:10.1016/j.neuroimage.2018.09.068

Hirschfeld, T., & Schmidt, T. T. (2020). How does it feel to be on psilocybin? Dose-response
relationships of subjective experiences in humans. *bioRxiv*, 2020.2006.2009.142802.
doi:10.1101/2020.06.09.142802

Jamieson, A. J., Harrison, B. J., Razi, A., & Davey, C. G. (2022). Rostral anterior cingulate network
effective connectivity in depressed adolescents and associations with treatment
response in a randomized controlled trial. *Neuropsychopharmacology, 47*(6), 1240-1248.
doi:10.1038/s41386-021-01214-z

Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: guidelines for
safety. In (Vol. 22, pp. 603-620). London, England.

Kandilarova, S., Stoyanov, D., Kostianev, S., & Specht, K. (2018). Altered Resting State Effective
Connectivity of Anterior Insula in Depression. *Frontiers in Psychiatry, 9*.
doi:10.3389/fpsyt.2018.00083

Kapur, S. (2003). Psychosis as a State of Aberrant Salience: A Framework Linking Biology,
Phenomenology, and Pharmacology in Schizophrenia. *American Journal of Psychiatry,*
160(1), 13-23. doi:10.1176/appi.ajp.160.1.13

Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012).
Psilocybin biases facial recognition, goal-directed behavior, and mood state toward
positive relative to negative emotions through different serotonergic subreceptors. *Biol*
Psychiatry, 72(11), 898-906. doi:10.1016/j.biopsych.2012.04.005

Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., &
Vollenweider, F. X. (2015). Psilocybin-Induced Decrease in Amygdala Reactivity
Correlates with Enhanced Positive Mood in Healthy Volunteers. *Biological Psychiatry,*
78(8), 572-581. doi:10.1016/j.biopsych.2014.04.010

Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015).
Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.
Human Brain Mapping, 36(8), 3137-3153. doi:10.1002/hbm.22833

Luppi, A. I., Carhart-Harris, R. L., Roseman, L., Pappas, I., Menon, D. K., & Stamatakis, E. A.
(2021). LSD alters dynamic integration and segregation in the human brain.
NeuroImage, 227, 117653. doi:https://doi.org/10.1016/j.neuroimage.2020.117653

Malinowski, P. (2013). Neural mechanisms of attentional control in mindfulness meditation.
Front Neurosci, 7, 8. doi:10.3389/fnins.2013.00008

Matias, S., Lottem, E., Dugué, G. P., & Mainen, Z. F. (2017). Activity patterns of serotonin
neurons underlying cognitive flexibility. *eLife, 6*, e20552. doi:10.7554/eLife.20552
McRae, K., Misra, S., Prasad, A. K., Pereira, S. C., & Gross, J. J. (2012). Bottom-up and top-down
emotion generation: implications for emotion regulation. *Social cognitive and affective*
neuroscience, 7(3), 253-262. doi:10.1093/scan/nsq103
Millière, R., Carhart-Harris, R. L., Roseman, L., Trautwein, F.-M., & Berkovich-Ohana, A. (2018).
Psychedelics, Meditation, and Self-Consciousness. *Frontiers in Psychology, 9*(1475).
doi:10.3389/fpsyg.2018.01475
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J., Brookes, M. J., Williams, T. M.,
Errtizoe, D., . . . Nutt, D. J. (2013). Broadband Cortical Desynchronization Underlies the
Human Psychedelic State. *The Journal of Neuroscience, 33*(38), 15171-15183.
doi:10.1523/jneurosci.2063-13.2013
Northoff, G. (2007). Psychopathology and pathophysiology of the self in depression -
neuropsychiatric hypothesis. *J Affect Disord, 104*(1-3), 1-14.
doi:10.1016/j.jad.2007.02.012
Nutt, D., & Carhart-Harris, R. (2020). The Current Status of Psychedelics in Psychiatry. *JAMA*
Psychiatry. doi:10.1001/jamapsychiatry.2020.2171
Ochsner, K. N., Ray, R. R., Hughes, B., McRae, K., Cooper, J. C., Weber, J., . . . Gross, J. J. (2009).
Bottom-up and top-down processes in emotion generation: common and distinct neural
mechanisms. *Psychol Sci, 20*(11), 1322-1331. doi:10.1111/j.1467-9280.2009.02459.x
Park, J., Wood, J., Bondi, C., Del Arco, A., & Moghaddam, B. (2016). Anxiety Evokes
Hypofrontality and Disrupts Rule-Relevant Encoding by Dorsomedial Prefrontal Cortex
Neurons. *The Journal of Neuroscience, 36*(11), 3322-3335. doi:10.1523/jneurosci.4250-
15.2016
Paulesu, E., Sambugaro, E., Torti, T., Danelli, L., Ferri, F., Scialfa, G., . . . Sassaroli, S. (2010).
Neural correlates of worry in generalized anxiety disorder and in normal controls: a
functional MRI study. *Psychol Med, 40*(1), 117-124. doi:10.1017/s0033291709005649
Paulus, M. (2006). An Insular View of Anxiety. *Biol.Psychiatry, 60*, 383-387.
doi:10.1016/j.biopsych.2006.03.042
Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017). Effect of
Psilocybin on Empathy and Moral Decision-Making. *International Journal of*
Neuropsychopharmacology, 20(9), 747-757. doi:10.1093/ijnp/pyx047
Preller, K. H., Burt, J. B., Ji, J. L., Schleifer, C. H., Adkinson, B. D., Stämpfli, P., . . . Anticevic, A.
(2018). Changes in global and thalamic brain connectivity in LSD-induced altered states
of consciousness are attributable to the 5-HT2A receptor. *eLife, 7*, e35082.
doi:10.7554/eLife.35082
Preller, K. H., Duerler, P., Burt, J. B., Ji, J. L., Adkinson, B., Stämpfli, P., . . . Vollenweider, F. X.
(2020). Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity.
Biological Psychiatry, 88(2), 197-207.
doi:https://doi.org/10.1016/j.biopsych.2019.12.027
Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stampfli, P., . . .
Vollenweider, F. X. (2017). The Fabric of Meaning and Subjective Effects in LSD-Induced
States Depend on Serotonin 2A Receptor Activation. *Curr Biol, 27*(3), 451-457.
doi:10.1016/j.cub.2016.12.030

Preller, K. H., Pokorny, T., Kraehenmann, R., Scheidegger, M., Dziobek, I., Staempfli, P., &
Vollenweider, F. X. (2015). The 5-HT2A/1A agonist psilocybin reduces social pain and
enhances empathy in healthy volunteers. *European Neuropsychopharmacology, 25*,
S301-S301. doi:10.1016/s0924-977x(15)30364-3
Preller, K. H., Razi, A., Zeidman, P., Stämpfli, P., Friston, K. J., & Vollenweider, F. X. (2019).
Effective connectivity changes in LSD-induced altered states of consciousness in
humans. *Proceedings of the National Academy of Sciences, 116*(7), 2743-2748.
doi:10.1073/pnas.1815129116
Qin, P., & Northoff, G. (2011). How is our self related to midline regions and the default-mode
network? *NeuroImage, 57*(3), 1221-1233. doi:10.1016/j.neuroimage.2011.05.028
Raichle, M. E. (2015). The brain's default mode network. *Annu Rev Neurosci, 38*, 433-447.
doi:10.1146/annurev-neuro-071013-014030
Razi, A., Kahan, J., Rees, G., & Friston, K. J. (2015). Construct validation of a DCM for resting
state fMRI. *NeuroImage, 106*, 1-14.
doi:https://doi.org/10.1016/j.neuroimage.2014.11.027
Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018). Increased
amygdala responses to emotional faces after psilocybin for treatment-resistant
depression. *Neuropharmacology, 142*, 263-269.
doi:https://doi.org/10.1016/j.neuropharm.2017.12.041
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of Acute Psychedelic Experience
Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. *Frontiers*
in Pharmacology, 8, 974. doi:10.3389/fphar.2017.00974
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., . . . Schmidt, B. L. (2016).
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and
depression in patients with life-threatening cancer: a randomized controlled trial.
Journal of Psychopharmacology, 30(12), 1165-1180. doi:10.1177/0269881116675512
Rotge, J. Y., Lemogne, C., Hinfray, S., Huguet, P., Grynszpan, O., Tartour, E., . . . Fossati, P.
(2015). A meta-analysis of the anterior cingulate contribution to social pain. *Social*
cognitive and affective neuroscience, 10(1), 19-27. doi:10.1093/scan/nsu110
Saulin, A., Savli, M., & Lanzenberger, R. (2012). Serotonin and molecular neuroimaging in
humans using PET. *Amino Acids, 42*(6), 2039-2057. doi:10.1007/s00726-011-1078-9
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., . . . Dunbar, G. C.
(1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development
and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J*
Clin Psychiatry, 59 Suppl 20, 22-33;quiz 34-57.
Smigielski, L., Kometer, M., Scheidegger, M., Stress, C., Preller, K. H., Koenig, T., & Vollenweider,
F. X. (2020). P300-mediated modulations in self-other processing under psychedelic
psilocybin are related to connectedness and changed meaning: A window into the self-
other overlap. *Hum Brain Mapp, 41*(17), 4982-4996. doi:10.1002/hbm.25174
Stoliker, D., Egan, G., Friston, K., & Razi, A. (2021). Neural Mechanisms and Psychology of
Psychedelic Ego Dissolution. In: PsyArXiv.
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022). Neural Mechanisms and Psychology of
Psychedelic Ego Dissolution. *Pharmacological Reviews, 74*(4), 874.
doi:10.1124/pharmrev.121.000508

Stoliker, D., Egan, G. F., & Razi, A. (2022). Reduced Precision Underwrites Ego Dissolution and
Therapeutic Outcomes Under Psychedelics. *Frontiers in Neuroscience, 16*.
doi:10.3389/fnins.2022.827400
Stoliker, D., Novelli, L., Vollenweider, F. X., Egan, G. F., Preller, K. H., & Razi, A. (2021). Effective
connectivity of LSD-induced ego dissolution. *medRxiv*, 2021.2012.2028.21268391.
doi:10.1101/2021.12.28.21268391
Stoliker, D., Novelli, L., Vollenweider, F. X., Egan, G. F., Preller, K. H., & Razi, A. (2022). Effective
connectivity of functionally anticorrelated networks under LSD. *Biological Psychiatry*.
doi:10.1016/j.biopsych.2022.07.013
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012). Prediction of Psilocybin
Response in Healthy Volunteers. *Plos One, 7*(2). doi:10.1371/journal.pone.0030800
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010). Psychometric evaluation of the altered
states of consciousness rating scale (OAV). *Plos One, 5*(8), e12412-e12412.
doi:10.1371/journal.pone.0012412
Swanson, L. R. (2018). Unifying Theories of Psychedelic Drug Effects. *Frontiers in Pharmacology,
9*(172). doi:10.3389/fphar.2018.00172
Tagliazucchi, E., Carhart-Harris, R., Leech, R., Nutt, D., & Chialvo, D. R. (2014). Enhanced
repertoire of brain dynamical states during the psychedelic experience. *Human Brain
Mapping, 35*(11), 5442-5456. doi:10.1002/hbm.22562
Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., . . .
Carhart-Harris, R. (2016). Increased Global Functional Connectivity Correlates with LSD-
Induced Ego Dissolution. *Current biology: CB, 26*(8), 1043-1050.
doi:10.1016/j.cub.2016.02.010
Terasawa, Y., Shibata, M., Moriguchi, Y., & Umeda, S. (2013). Anterior insular cortex mediates
bodily sensibility and social anxiety. *Social cognitive and affective neuroscience, 8*(3),
259-266. doi:10.1093/scan/nss108
Underwood, R., Tolmeijer, E., Wibroe, J., Peters, E., & Mason, L. (2021). Networks underpinning
emotion: A systematic review and synthesis of functional and effective connectivity.
NeuroImage, 243, 118486. doi:10.1016/j.neuroimage.2021.118486
Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Maguire, P., Stadelmann, O., & Angst, J.
(1997). Positron emission tomography and fluorodeoxyglucose studies of metabolic
hyperfrontality and psychopathology in the psilocybin model of psychosis.
Neuropsychopharmacology, 16(5), 357-372. doi:10.1016/s0893-133x(96)00246-1
Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: neurobiology and potential for
treatment of psychiatric disorders. *Nature Reviews Neuroscience, 21*(11), 611-624.
doi:10.1038/s41583-020-0367-2
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Babler, A., Vogel, H., & Hell, D.
(1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2
agonist action. *Neuroreport, 9*(17), 3897-3902. doi:10.1097/00001756-199812010-
00024
Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients' Accounts of
Increased "Connectedness" and "Acceptance" After Psilocybin for Treatment-Resistant
Depression. *Journal of Humanistic Psychology, 57*(5), 520-564.
doi:10.1177/0022167817709585

Watts, R., Kettner, H., Geerts, D., Gandy, S., Kartner, L., Mertens, L., . . . Roseman, L. (2022). The
Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self,
others, and world. *Psychopharmacology*. doi:10.1007/s00213-022-06187-5
Watts, R., & Luoma, J. B. (2020). The use of the psychological flexibility model to support
psychedelic assisted therapy. *Journal of Contextual Behavioral Science, 15*, 92-102.
doi:https://doi.org/10.1016/j.jcbs.2019.12.004
Wiebking, C., de Greck, M., Duncan, N. W., Tempelmann, C., Bajbouj, M., & Northoff, G. (2015).
Interoception in insula subregions as a possible state marker for depression—an
exploratory fMRI study investigating healthy, depressed and remitted participants.
Frontiers in Behavioral Neuroscience, 9. doi:10.3389/fnbeh.2015.00082
Yarkoni, T., Poldrack, R. A., Nichols, T. E., Van Essen, D. C., & Wager, T. D. (2011). Large-scale
automated synthesis of human functional neuroimaging data. *Nature Methods, 8*(8),
665-670. doi:10.1038/nmeth.1635
Zhou, Y., Friston, K. J., Zeidman, P., Chen, J., Li, S., & Razi, A. (2018). The Hierarchical
Organization of the Default, Dorsal Attention and Salience Networks in Adolescents and
Young Adults. *Cereb Cortex, 28*(2), 726-737. doi:10.1093/cercor/bhx307
812
813